We are looking for a collaboration with a pharmaceutical company to develop and validate new models of neurodegenerative disease for target validation and compound screening....
Read more...
We are seeking active collaborators from the pharmaceutical or biotechnology sector for co-development of novel 3D cell-based assays and models. Our ideal partner would provide cell and tissue specific expertise on their model of choice and potentially compounds for testing within the model. We would provide expertise in, and conduct, short- to long-term perfused 3D cell-based experiments spanning single chamber, segregated co-culture or 3D migration set-ups. We could provide access to primary tissue and cells if appropriate....
Read more...
We are looking for a collaboration with the pharmaceutical or biotechnology sector to develop and validate primary cell cultures for inter-species comparisons of renal toxicity between toxicologically relevant species and man. The current animal testing regime for drug molecules in late development pipelines is poorly predictive of ‘first in man’ toxicity. Renal issues account for around 25% of failures and there is a lack of good robust and predictive in vitro renal cell models....
Read more...
FibromEd Ltd is keen to develop partnerships with the pharmaceutical industry, contract research organisations and the chemical industry to develop and validate our HepatoinformTM platform for assessing hepatotoxicity. We are open to exploring a variety of options for partnerships from companies interested in screening their internal compounds through to companies who provide sophisticated screening platforms for drug discovery, chemical standards and research materials for others. ...
Read more...